Durin Technologies Receives Additional Funding to Accelerate Growth
December 05, 2023 10:00 ET
|
Durin Technologies
Stratford, NJ, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced funding of...
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
December 04, 2023 16:35 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
December 04, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of...
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
December 04, 2023 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,...
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
November 29, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of...
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023 07:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders
November 09, 2023 08:30 ET
|
PHARMA TWO B LTD
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and dopaminergic side effects...
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
November 07, 2023 10:41 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer's disease, affecting an estimated one...
Groundbreaking study reveals link between air pollution and incidence of Parkinson’s disease
October 31, 2023 18:07 ET
|
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
Phoenix, Oct. 31, 2023 (GLOBE NEWSWIRE) -- A new study led by researchers at Barrow Neurological Institute has found that people living in regions with median levels of air pollution have a 56...
Digital Brain Health Market Predicted to Reach US$ 382.9 billion by 2031, Growing at a 7.3% CAGR Says, Transparency Market Research
October 26, 2023 04:33 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The digital brain health market was valued at US$ 184.7 billion in 2021. The market is...